viewValiRx PLC

ValiRx Plc gets go-ahead for trials of lung cancer drug

Life science group ValiRx Plc (LON:VAL) has got the green light to start trials of a flagship lung cancer drug.
ValiRx has received approval from authorities in the former Soviet republic of Georgia to begin dosing patients in a phase II clinical trial of VAL401.
The news means ValiRx's joint venture ValiSeek to start identifying  and recruiting people for screening.
ValiSeek's chief executive Suzanne Dilly said: "It is very satisfying to have received confirmation from the regulatory experts that the trial has been correctly constructed and that the process of selecting patients for dosing can begin.
"After several years of preparation and pre-clinical testing, it is exciting to know we can expect results to start arriving in the coming months."

Quick facts: ValiRx PLC

Price: 25.25 GBX

Market: AIM
Market Cap: £16.38 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...


ValiRx Plc enjoying strong industry interest in its cancer treatments

George Morris, chief operations officer at ValiRx Plc (LON:VAL), updates Proactive's Andrew Scott on developments across the company's portfolio. Morris says advanced conversations are continuing with possible partners as they look to press ahead with the development of their flagship...

on 19/7/18

2 min read